43 related articles for article (PubMed ID: 10720564)
1. The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9.
Tong Y; Yu Z; Chen Z; Zhang R; Ding X; Yang X; Niu X; Li M; Zhang L; Billiar TR; Pitt BR; Li Q
Cell Death Dis; 2021 Jan; 12(1):67. PubMed ID: 33431821
[TBL] [Abstract][Full Text] [Related]
2. Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells.
Yang S; Chen Y; Gu K; Dash A; Sayre CL; Davies NM; Ho EA
Int J Nanomedicine; 2013; 8():2847-58. PubMed ID: 23966779
[TBL] [Abstract][Full Text] [Related]
3. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.
Gulati A; Gerk PM
J Pharm Sci; 2009 Jul; 98(7):2317-35. PubMed ID: 19067393
[TBL] [Abstract][Full Text] [Related]
4. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
Moltó J; Blanco A; Miranda C; Miranda J; Puig J; Valle M; Delavarga M; Fumaz CR; Barbanoj MJ; Clotet B
Br J Clin Pharmacol; 2007 Jun; 63(6):715-21. PubMed ID: 17223856
[TBL] [Abstract][Full Text] [Related]
5. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
Moltó J; Blanco A; Miranda C; Miranda J; Puig J; Valle M; DelaVarga M; Fumaz CR; Barbanoj MJ; Clotet B
Br J Clin Pharmacol; 2006 Nov; 62(5):560-6. PubMed ID: 17061963
[TBL] [Abstract][Full Text] [Related]
6. Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
Kappelhoff BS; Crommentuyn KM; de Maat MM; Mulder JW; Huitema AD; Beijnen JH
Clin Pharmacokinet; 2004; 43(13):845-53. PubMed ID: 15509183
[TBL] [Abstract][Full Text] [Related]
7. Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.
Patel J; Pal D; Vangal V; Gandhi M; Mitra AL
Pharm Res; 2002 Nov; 19(11):1696-703. PubMed ID: 12458676
[TBL] [Abstract][Full Text] [Related]
8. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
11. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
12. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
13. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
14. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
15. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
